Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.08%
As of Monday, July 27, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.08%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 5.64%
As of Friday, July 10, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.21%
As of Thursday, July 09, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.54%
As of Thursday, July 02, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.54%, which has investors questioning if this is right time to sell.Michael Rose
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.09%
As of Monday, June 29, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 5.09%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $906.3 | $252.6 | 44% |
|
| Shares Out (Mil) | 5.7 | 52.3 | 15% |
|
| Institutional Ownership | 83.9% | 92.1% | 52% |
|
| Float (Mil) | 23.9 | 40.2 | 32% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 165 | 455 | 42% |
|
| Price Change (52-week) |
na | 52.9% | na |
|
| Growth | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 3 | |
| Current EPS | ($0.850) | ($4.546) | ($3.876) | |
| Month Ago EPS | ($0.850) | ($4.546) | ($3.876) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (87.4%) | (90.9%) | (91.9%) | |
| Financials | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 2% |
|
| Net Income (TTM) (Mil) | ($149) | ($43) | 8% |
|
| EPS (TTM) | ($35.905) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $21 | $5 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,349 | $180 | 45% |
|
| Valuation | ODTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (129.6%) | (49.8%) | 4% |
|
| ROE | 56.7% | (55.5%) | 93% |
|
| Liabilities to Assets | 21.5% | 30.3% | 14% |
|
| F-Score | 1 | 3 | na |
|
Odyssey Therapeutics, Inc. did not pass any screens on 7/31/2026.
